The importance of vascular endothelial growth factor and polymorphism of the VEGF a gene (g634c) in the development of steatosis, fibrosis and cirrhosis of the liver patients in the city of Perm

Introduction. Chronic liver diseases are a significant medical problem all over the world. To date, there is a need to develop a set of laboratory tests, including genetic ones, to determine the risk of development and progression of steatosis, fibrosis and cirrhosis of the liver of various etiologies. Aim: To investigate the serum concentration of vasculoendothelial growth factor (VEGF) and the frequency of occurrence of VEGFA gene polymorphism genotypes in the region -634G/C (rs2010963) in patients with steatosis, fibrosis and cirrhosis of the liver in the Perm Region. Materials and methods: 258 people were examined, including 52 patients with non-alcoholic liver steatosis, 95 patients with chronic hepatitis C and liver fibrosis, 46 people with cirrhosis of the liver of viral (HCV) and alcoholic etiology and 65 practically healthy individuals. The serum concentration of VEGF was determined by enzyme immunoassay. Polymorphisms of the VEGFA gene in region -634G/C were analyzed by polymerase chain reaction. Result: The development of steatosis, fibrosis and cirrhosis of the liver is accompanied by endothelial damage with activation of neoangiogenesis due to hyperproduction of VEGF (p=0.001, p=0.0001 and p=0.001, respectively) in the blood serum. Elevated serum VEGF values in patients confirmed the presence of endothelial dysfunction in liver pathology. The study of the single nucleotide polymorphism of the VEGFA gene (G634C) showed a higher incidence of recessive allele C in patients with steatosis and cirrhosis in 54.81% (p=0.01) and 48.9% (p=0.04) of cases than in the control group -37.69%, which suggested the presence of an association of the carrier of allele C of this polymorphism in the form of genotypes CC or GC with a risk of developing steatosis and cirrhosis of the liver. Conclusion. Determination of the genetic marker VEGFA in the region -634G/C allows us to assess the increased risk of developing chronic liver diseases when exposed to various etiological factors.

vascular endothelial growth factor (VEGF), steatosis, fibrosis, cirrhosis, gene polymorphism

1. Moon A.M., Singal A. G., Tapper E. B. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2020 Nov;18(12):2650-2666. doi: 10.1016/j.cgh.2019.07.060.

2. Shenoda B., Boselli J. Vascular syndromes in liver cirrhosis. Clin J Gastroenterol. 2019 Oct;12(5):387-397. doi: 10.1007/s12328-019-00956-0.

3. Shchekotov V. V., Shchekotova A. P., Bulatova I. A. Relationship of the markers of endothelial dysfunction and fibrosis in chronic hepatitis and cirrhosis. The Clinician. 2011;5(3):68-72. (In Russ.) doi: 10.17650/1818-8338-2011-3-68-72.@@ Щёкотов В. В., Щёкотова А. П., Булатова И. А. Взаимосвязь маркеров эндотелиальной дисфункции и фиброза при хроническом гепатите и циррозе печени. Клиницист. 2011;5(3):68-72. doi: 10.17650/1818-8338-2011-3-68-72.

4. Yang L., Kwon J., Popov Y., Gajdos G. B., Ordog T., Brekken R. A., Mukhopadhyay D., Schuppan D., Bi Y., Simonetto D., Shah V. H. Vascular Endothelial Growth Factor Promotes Fibrosis Resolution and Repair in Mice. Gastroenterology. 2014 May;146(5):1339-50.e1. doi: 10.1053/j.gastro.2014.01.061.

5. Bykova G. A., Khlynova O. V., Tuev A. V. Characteristics of external respiration function and the state of the endothelium in patients with non-alcoholic fatty liver disease. Family health - 21st century. 2018; 1 (1): 16-24. (In Russ.) Available at: http://fh-21.perm.ru/download/2018-1/2018-1-16-24.pdf@@ Быкова Г. А., Хлынова О. В., Туев А. В. Особенности функции внешнего дыхания и состояния эндотелия у пациентов с неалкогольной жировой болезнью печени. Здоровье семьи - 21 век. 2018; 1 (1): 16-24.Режим доступа: http://fh-21.perm.ru/download/2018-1/2018-1-16-24.pdf

6. LeСouter J., Moritz D. R., Li B., Phillips G. L., Liang X. H., Gerber H. P., Hillan K. J., Ferrara N. Angiogenesis-independent endothelial protection of liver: role of VEGF. Science. 2003 Feb 7;299(5608):890-3. doi: 10.1126/science.1079562.

7. Drapkina O.M., Deeva T. A., Ivashkin V. T. Evaluation of endothelial function and estimation of the degree of apoptosis in patients with metabolic syndrome and non-alcoholic fatty liver disease. Terapevtic arkhive. 2015;87(5):76-83. (In Russ.)@@ Драпкина О. М., Деева Т. А., Ивашкин В. Т. Оценка эндотелиальной функции и степени апоптоза у пациентов с метаболическим синдромом и неалкогольной жировой болезнью печени. Терапевтический архив. 2015;87(5):76-83.

8. Bosch J., Abraldes J. G., Fernández M., García-Pagán J. C. Hepatic endothelial dysfunction and abnormal angiogenesis: New targets in the treatment of portal hypertension. J Hepatol. 2010 Sep;53(3):558-67. doi: 10.1016/j.jhep.2010.03.021.

9. Ng S.W.K, Rouhani F. J., Brunner S.F, Brzozowska N., Aitken S. J., Yang M. et al. Convergent somatic mutations in metabolism genes in chronic liver disease. Nature. 2021 Oct;598(7881):473-478. doi: 10.1038/s41586-021-03974-6.

10. De Chiara F., Heeboll S., Marrone G. et al. Urea cycle dysregulation in non-alcoholic fatty liver disease. J Hepatol. 2018 Oct;69(4):905-915. doi: 10.1016/j.jhep.2018.06.023.

11. Hardy T., Zeybel М., Day С. Р. Dipper С., Masson S. et al. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut. 2017 Jul;66(7):1321-1328. doi: 10.1136/gutjnl-2016-311526.

12. Sookoian S., Pirola C. I. Genetics of nonalcoholic fatty liver disease: from pathogenesis to therapeutics. Semin Liver Dis. 2019 May;39(2):124-140. doi: 10.1055/s-0039-1679920.

13. Kovalic A. J., Banerjee Р., Tran Q. T., Singal А. К., Satapathy S. K. Genetic and Epigenetic Culprits in the Pathogenesis of Nonalcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2018 Dec;8(4):390-402. doi: 10.1016/j.jceh.2018.04.001.

14. Taratina O.V., Krasnova T. N., Samokhodskaia L. M., Lopatkina T. N., Tkachuk V. A., Mukhin N. A. Endothelial dysfunction gene polymorphisms and the rate of liver fibrosis in chronic hepatitis C. Terapevtic arkhive. 2014; 86(4):45-51. (In Russ.)@@ Таратина О. В., Краснова Т. Н., Самоходская Л. М., Лопаткина Т. Н., Ткачук В. А., Мухин Н. А. Полиморфизм генов дисфункции эндотелия и скорость прогрессирования фиброза печени при хроническом гепатите С. Терапевтический архив. 2014; 86(4): 45-51.

15. Huang H., Shiffman M. L., Friedman S., Venkatesh R., Bzowej N., Abar O. T. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology. 2007 Aug;46(2):297-306. doi: 10.1002/hep.21695.

16. Angeli P., Bernardi M. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Aug;69(2):406-460. doi: 10.1016/j.jhep.2018.03.024.

17. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018 Jul;69(1):154-181. doi: 10.1016/j.jhep.2018.03.018.

18. Albillos A., Lario М., Alvarez-Mon М. Cirrosis-associated immune distinctive features and clinical relevance. J Hepatol. 2014 Dec;61(6):1385-96. doi: 10.1016/j.jhep.2014.08.010.

19. Dirchwolf М., Podhorzer А., Morino М. et al. Immune dysfunction in cirrhosis: Distinct cytokines phenotypes according to cirrhosis severity. Cytokine. 2016 Jan;77:14-25. doi: 10.1016/j.cyto.2015.10.006.

20. Martínez-Esparza M., Tristán-Manzano M., Ruiz-Alcaraz A.J., García-Peñarrubia P. Inflammatory status in human hepatic cirrhosis. World J Gastroenterol. 2015 Nov 7;21(41):11522-41. doi: 10.3748/wjg.v21.i41.11522.

21. Shchekotova A. P., Bulatova I. A. Role of vasculoendothelial growth factor and its gene in the pathogenesis of hepatobiliary pathology. Permskiy meditsinskiy zhurnal. 2020; 4(37): 36-45. (In Russ.) doi: 10.31146/1682-8658-ecg-189-5-39-43.@@ Щёкотова А. П., Булатова И. А. Роль васкулоэндотелиального фактора роста и его гена в патогенезе гепатобилиарной патологии. Пермский медицинский журнал. 2020; 4(37): 36-45. doi: 10.31146/1682-8658-ecg-189-5-39-43.

22. Dolgikh O.V, Paducheva S. V., Bulatova I. A., Shyokotova A. P. Peculiarities of the immunological response during liver cirrhosis depending on severity level.Russian Journal of Immunology 2017; 20(3): 463-465. (In Russ.)@@ Долгих О. В., Падучева С. В., Булатова И. А., Щекотова А. П. Особенности иммунологического ответа при циррозе печени в зависимости от степени его тяжести. Российский иммунологический журнал. 2017; 20(3): 463-465.

23. Geyvandova N. I., Nigiyan Z. V., Babasheva G. G. Role of endothelial dysfunction in the formation of non-alcoholic steatohepatitis. Medical Bulletin of the North Caucasus. 2015; 2(10): 183-187. (In Russ.) doi: 10.14300/mnnc.2015.10043.@@ Гейвандова Н. И., Нигиян З. В., Бабашева Г. Г. Роль эндотелиальной дисфункции в формировании неалкогольного стеатогепатита. Медицинский вестник Северного Кавказа. 2015; 2(10): 183-187. doi: 10.14300/mnnc.2015.10043.

24. Coulon S., Francque S., Colle I. et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine. 2012 Aug;59(2):442-9. doi: 10.1016/j.cyto.2012.05.001.

25. Gulyaeva I. L., Bulatova I. A., Pestrenin L. D. Role of vascular endothelial growth factor in the pathogenesis of hepatic steatosis and dyslipidemia. Pathological physiology and experimental therapy. 2020; 4(64): 31-36. (In Russ.) doi: 10.25557/0031-2991.2020.04.31-36.@@ Гуляева И. Л., Булатова И. А., Пестренин Л. Д. Роль васкулоэндотелиального фактора роста в патогенезе стеатоза печени и дислипидемии. Патологическая физиология и экспериментальная терапия. 2020; 64(4): 31-36. doi: 10.25557/0031-2991.2020.04.31-36.

26. Krivosheev A. B., Maximov V. N., Boyko K. Yu., Levykina E. E., Kondratova M. A., Tov N. L. Molecular genetic studies in chronic diffuse liver diseases. Experimental and Clinical Gastroenterology. 2020;182(10): 96-100. (In Russ.) doi: 10.31146/1682-8658-ecg-182-10-96-100.@@ Кривошеев А. Б., Максимов В. Н., Бойко К. Ю., Левыкина Е. Е., Кондратова М. А., Тов Н. Л. Молекулярно-генетические исследования при хронических диффузных заболеваниях печени. Экспериментальная и клиническая гастроэнтерология. 2020; (10):96-100. doi: 10.31146/1682-8658-ecg-182-10-96-100.